GAMMA Investing LLC Boosts Stock Position in Intuitive Surgical, Inc. $ISRG

Key Points

• GAMMA Investing LLC has increased its stake in Intuitive Surgical, Inc. by 10.1%, holding 6,734 shares valued at approximately $3.66 million.
• Wall Street analysts are optimistic, with multiple brokerages raising their target prices for Intuitive Surgical, culminating in an average target price of $595.95 and a consensus rating of "Moderate Buy."
• Insider trading has seen significant activity, with insiders selling a total of 45,224 shares worth over $21.7 million in the past three months.

GAMMA Investing LLC raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 10.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,734 shares of the medical equipment provider's stock after acquiring an additional 619 shares during the quarter. GAMMA Investing LLC's holdings in Intuitive Surgical were worth $3,659,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Chilton Capital Management LLC boosted its position in shares of Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Global Financial Private Client LLC boosted its position in shares of Intuitive Surgical by 253.3% in the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares in the last quarter. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical in the 1st quarter worth $26,000. LFA Lugano Financial Advisors SA acquired a new stake in shares of Intuitive Surgical in the 1st quarter worth $30,000. Finally, TD Capital Management LLC boosted its position in shares of Intuitive Surgical by 300.0% in the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary S. Guthart sold 29,360 shares of Intuitive Surgical stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $472.49, for a total value of $13,872,306.40. Following the completion of the transaction, the insider owned 19,827 shares of the company's stock, valued at approximately $9,368,059.23. This represents a 59.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,224 shares of company stock worth $21,716,492 in the last 90 days. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Trading Up 1.3%

Shares of NASDAQ ISRG traded up $5.83 during trading on Monday, reaching $444.55. 2,652,022 shares of the company traded hands, compared to its average volume of 2,373,186. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00. The firm's fifty day simple moving average is $475.20 and its 200 day simple moving average is $502.92. The stock has a market cap of $159.36 billion, a P/E ratio of 62.00, a PEG ratio of 4.60 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the previous year, the business earned $1.78 EPS. Intuitive Surgical's revenue for the quarter was up 21.4% compared to the same quarter last year. As a group, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ISRG. Evercore ISI raised their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. UBS Group boosted their price target on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. BTIG Research increased their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Piper Sandler reissued an "overweight" rating and issued a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.